232 related articles for article (PubMed ID: 24389432)
1. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
5. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
[TBL] [Abstract][Full Text] [Related]
6. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
10. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.
Vilmar A; Santoni-Rugiu E; Cillas JG; Huarriz M; Sørensen JB
Anticancer Res; 2014 Jun; 34(6):2991-6. PubMed ID: 24922664
[TBL] [Abstract][Full Text] [Related]
15. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the C-erbB-2 expression in turkish non-small cell lung cancer patients.
Calikusu Z; Yildirim Y; Akcali Z; Sakalli H; Bal N; Ozyilkan O
Asian Pac J Cancer Prev; 2009; 10(3):479-82. PubMed ID: 19640195
[TBL] [Abstract][Full Text] [Related]
18. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
[TBL] [Abstract][Full Text] [Related]
19. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]